Impact of a health safety warning and prior authorisation on the use of piroxicam: a time-series study
Version of Record online: 10 JAN 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 21, Issue 3, pages 281–284, March 2012
How to Cite
Carracedo-Martínez, E., Pia-Morandeira, A. and Figueiras, A. (2012), Impact of a health safety warning and prior authorisation on the use of piroxicam: a time-series study. Pharmacoepidem. Drug Safe., 21: 281–284. doi: 10.1002/pds.2275
- Issue online: 8 MAR 2012
- Version of Record online: 10 JAN 2012
- Manuscript Accepted: 17 OCT 2011
- Manuscript Revised: 19 AUG 2011
- Manuscript Received: 21 APR 2011
- peptic ulcer;
- drug utilisation
The aim of this study was to assess the quantitative changes in systemic use of piroxicam after the issue of a health safety warning about its risks and the subsequent implementation of prior authorisation.
We determined the number of monthly daily defined doses/1000 inhabitants/day (DHDs) of piroxicam in the period 2005–2008 in a health area in Spain. The data were analysed graphically, and the impact of the safety warning and introduction of prior authorisation were estimated by using segmented regression analysis.
The graph showed that the number of DHDs of piroxicam was stable both before and after the health safety warning but registered a very marked decrease after implementation of prior authorisation, after which DHDs of piroxicam remained stable at a 98% inferior level compared with previous to prior authorisation. Segmented regression analysis showed no statistically significant immediate jump in piroxicam utilisation after the safety warning nor a change in the slope afterwards, but it did show a significant immediate jump after prior authorisation.
Population exposure to systemic piroxicam remained unaffected by a previous health safety warning but declined sharply after the introduction of prior authorisation. Copyright © 2012 John Wiley & Sons, Ltd.